S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   271.89 (-0.22%)
AAPL   459.61 (-0.09%)
MSFT   208.82 (+0.06%)
FB   261.22 (-0.03%)
GOOGL   1,503.41 (-0.87%)
AMZN   3,146.88 (-0.45%)
NVDA   462.38 (+1.02%)
CGC   17.19 (-0.75%)
BABA   253.80 (+0.03%)
TSLA   1,649.30 (+1.75%)
GE   6.65 (+0.76%)
MU   45.60 (-1.17%)
AMD   81.27 (-0.70%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.55 (+0.25%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   177.90 (+1.81%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   271.89 (-0.22%)
AAPL   459.61 (-0.09%)
MSFT   208.82 (+0.06%)
FB   261.22 (-0.03%)
GOOGL   1,503.41 (-0.87%)
AMZN   3,146.88 (-0.45%)
NVDA   462.38 (+1.02%)
CGC   17.19 (-0.75%)
BABA   253.80 (+0.03%)
TSLA   1,649.30 (+1.75%)
GE   6.65 (+0.76%)
MU   45.60 (-1.17%)
AMD   81.27 (-0.70%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.55 (+0.25%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   177.90 (+1.81%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   271.89 (-0.22%)
AAPL   459.61 (-0.09%)
MSFT   208.82 (+0.06%)
FB   261.22 (-0.03%)
GOOGL   1,503.41 (-0.87%)
AMZN   3,146.88 (-0.45%)
NVDA   462.38 (+1.02%)
CGC   17.19 (-0.75%)
BABA   253.80 (+0.03%)
TSLA   1,649.30 (+1.75%)
GE   6.65 (+0.76%)
MU   45.60 (-1.17%)
AMD   81.27 (-0.70%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.55 (+0.25%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   177.90 (+1.81%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   271.89 (-0.22%)
AAPL   459.61 (-0.09%)
MSFT   208.82 (+0.06%)
FB   261.22 (-0.03%)
GOOGL   1,503.41 (-0.87%)
AMZN   3,146.88 (-0.45%)
NVDA   462.38 (+1.02%)
CGC   17.19 (-0.75%)
BABA   253.80 (+0.03%)
TSLA   1,649.30 (+1.75%)
GE   6.65 (+0.76%)
MU   45.60 (-1.17%)
AMD   81.27 (-0.70%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.55 (+0.25%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   177.90 (+1.81%)
Log in

NASDAQ:KALVKalvista Pharmaceuticals Stock Price, Forecast & News

$12.67
+0.22 (+1.77 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.00
Now: $12.67
$12.78
50-Day Range
$9.83
MA: $11.83
$12.97
52-Week Range
$5.61
Now: $12.67
$18.96
Volume2,566 shs
Average Volume133,921 shs
Market Capitalization$226.11 million
P/E RatioN/A
Dividend YieldN/A
Beta2.37
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.
Read More
Kalvista Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.69 million
Book Value$4.69 per share

Profitability

Net Income$-29,120,000.00
Net Margins-229.45%

Miscellaneous

Employees33
Market Cap$226.11 million
Next Earnings Date9/14/2020 (Estimated)
OptionableNot Optionable
$12.67
+0.22 (+1.77 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

How has Kalvista Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Kalvista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KALV shares have increased by 42.1% and is now trading at $12.59.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Kalvista Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kalvista Pharmaceuticals
.

When is Kalvista Pharmaceuticals' next earnings date?

Kalvista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, September 14th 2020.
View our earnings forecast for Kalvista Pharmaceuticals
.

How were Kalvista Pharmaceuticals' earnings last quarter?

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) announced its earnings results on Wednesday, July, 1st. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.28. The specialty pharmaceutical company earned $3.82 million during the quarter, compared to analyst estimates of $2.05 million. Kalvista Pharmaceuticals had a negative net margin of 229.45% and a negative return on equity of 31.21%.
View Kalvista Pharmaceuticals' earnings history
.

What price target have analysts set for KALV?

4 brokers have issued 12 month price objectives for Kalvista Pharmaceuticals' stock. Their forecasts range from $25.00 to $30.00. On average, they anticipate Kalvista Pharmaceuticals' share price to reach $28.33 in the next year. This suggests a possible upside of 125.0% from the stock's current price.
View analysts' price targets for Kalvista Pharmaceuticals
.

Has Kalvista Pharmaceuticals been receiving favorable news coverage?

Media coverage about KALV stock has been trending extremely negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a news impact score of -4.0 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Kalvista Pharmaceuticals
.

Are investors shorting Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 391,800 shares, an increase of 24.2% from the June 15th total of 315,500 shares. Based on an average daily trading volume, of 137,700 shares, the days-to-cover ratio is currently 2.8 days. Approximately 3.1% of the company's stock are sold short.
View Kalvista Pharmaceuticals' Short Interest
.

Who are some of Kalvista Pharmaceuticals' key competitors?

What other stocks do shareholders of Kalvista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Cara Therapeutics (CARA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), Crispr Therapeutics (CRSP), Viking Therapeutics (VKTX), Amarin (AMRN) and BioCryst Pharmaceuticals (BCRX).

Who are Kalvista Pharmaceuticals' key executives?

Kalvista Pharmaceuticals' management team includes the following people:
  • Mr. Thomas Andrew Crockett, CEO & Director (Age 44)
  • Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 53)
  • Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 56)
  • Mr. John B. McKune, VP of Fin. (Age 43)
  • Dr. Edward P. Feener, Chief Scientific Officer (Age 59)

What is Kalvista Pharmaceuticals' stock symbol?

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Who are Kalvista Pharmaceuticals' major shareholders?

Kalvista Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (9.88%), Ikarian Capital LLC (6.24%), Logos Global Management LP (3.15%), International Biotechnology Trust PLC (0.99%), Bank of New York Mellon Corp (0.24%) and Goldman Sachs Group Inc. (0.21%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par.
View institutional ownership trends for Kalvista Pharmaceuticals
.

Which institutional investors are selling Kalvista Pharmaceuticals stock?

KALV stock was sold by a variety of institutional investors in the last quarter, including International Biotechnology Trust PLC, FMR LLC, Alps Advisors Inc., Algert Global LLC, UBS Group AG, and Bank of America Corp DE. Company insiders that have sold Kalvista Pharmaceuticals company stock in the last year include Christopher Yea, and Thomas Andrew Crockett.
View insider buying and selling activity for Kalvista Pharmaceuticals
.

Which institutional investors are buying Kalvista Pharmaceuticals stock?

KALV stock was bought by a variety of institutional investors in the last quarter, including Logos Global Management LP, Ikarian Capital LLC, Goldman Sachs Group Inc., California Public Employees Retirement System, Dupont Capital Management Corp, Trexquant Investment LP, Quantitative Systematic Strategies LLC, and Bank of New York Mellon Corp. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha, and Daniel B Soland.
View insider buying and selling activity for Kalvista Pharmaceuticals
.

How do I buy shares of Kalvista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kalvista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $12.59.

How big of a company is Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals has a market capitalization of $224.68 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-29,120,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.

What is Kalvista Pharmaceuticals' official website?

The official website for Kalvista Pharmaceuticals is www.kalvista.com.

How can I contact Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.